Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/200576
Type: Artigo
Title: Osteonecrosis of the mandible associated with bevacizumab therapy
Author: Santos-Silva, Alan Roger
Belizário Rosa, Giuliano Augusto
Castro Júnior, Gilberto de
Dias, Reinaldo Brito
Prado Ribeiro, Ana Carolina
Brandão, Thaís Bianca
Abstract: Bevacizumab is a humanized antibody that blocks vascular endothelial growth factor and is of great value for the treatment of advanced cancer. Several adverse effects following its administration have been reported. To date, only 8 cases of osteonecrosis of the jaws associated with bevacizumab (without any association with bisphosphonates) have been reported. The aim of this article was to describe an original case of bevacizumab-related osteonecrosis of the jaw. A 61-year-old man diagnosed with advanced renal cell carcinoma was undergoing treatment with intravenous bevacizumab and temsirolimus when he spontaneously developed mandible osteonecrosis, which resolved after 3 months of conservative management. The present case reinforces recent speculation that the anti-angiogenic properties of bevacizumab may represent a potential new source of osteonecrosis of the jaws in patients undergoing cancer treatment. Multidisciplinary teams in cancer care should be aware of the possible association between osteonecrosis of the jaw and bevacizumab therapy.
Bevacizumab is a humanized antibody that blocks vascular endothelial growth factor and is of great value for the treatment of advanced cancer. Several adverse effects following its administration have been reported. To date, only 8 cases of osteonecrosis of the jaws associatedwith bevacizumab (without any association with bisphosphonates) have been reported. The aim of this article was to describe an original case of bevacizumab-related osteonecrosis of the jaw. A 61-year-old man diagnosed with advanced renal cell carcinoma was undergoing treatment with intravenous bevacizumab and temsirolimus when he spontaneously developed mandible osteonecrosis, which resolved after 3 months of conservative management. The present case reinforces recent speculation that the anti-angiogenic properties of bevacizumabmay represent a potential new source of osteonecrosis of the jaws in patients undergoing cancer treatment. Multidisciplinary teams in cancer care should be aware of the possible association between osteonecrosis of the jaw and bevacizumab therapy
Subject: Osteonecrose
Mandíbula
Country: Holanda
Editor: Elsevier
Citation: Oral Surgery, Oral Medicine, Oral Pathology And Oral Radiology. v. 115, n. 6, p. e32-6, 2013-Jun.
Rights: fechado
Identifier DOI: 10.1016/j.oooo.2013.02.001
Address: https://www.sciencedirect.com/science/article/pii/S2212440313000539
Date Issue: 2013
Appears in Collections:FOP - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
23567260.pdf464.72 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.